A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Isatuximab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms LenCombo
- Sponsors Sanofi
- 11 Jul 2017 Planned End Date changed from 1 Sep 2018 to 28 Dec 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Sep 2018 to 28 Dec 2018.
- 10 Jun 2017 Biomarkers information updated